Clinical Trials · NCT00903162
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 17
- Start date
- May 2009
- Locations
- 4 sites, United States
- Primary endpoint
- Tolerability at One Year of Ovarian Function Suppression (OFS) Using Leuprolide and Letrozole.